Scott Wise

2.5k total citations
43 papers, 1.2k citations indexed

About

Scott Wise is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Scott Wise has authored 43 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 13 papers in Molecular Biology and 10 papers in Genetics. Recurrent topics in Scott Wise's work include Chronic Myeloid Leukemia Treatments (10 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Scott Wise is often cited by papers focused on Chronic Myeloid Leukemia Treatments (10 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Scott Wise collaborates with scholars based in United States and Switzerland. Scott Wise's co-authors include Todd Leff, Michael J. Birrer, Anita L. Sabichi, Powel H. Brown, Daniel L. Flynn, Bryan D. Smith, Mingfu Wang, Yanguo Hong, Heidi S. Camp and Xun Shen and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Scott Wise

39 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Scott Wise United States 17 660 293 195 179 161 43 1.2k
Karoline Kollmann Austria 18 629 1.0× 413 1.4× 114 0.6× 234 1.3× 180 1.1× 31 1.2k
Severa Bunda Canada 18 608 0.9× 150 0.5× 196 1.0× 79 0.4× 177 1.1× 27 1.0k
Annelie Abrahamsson Sweden 18 947 1.4× 644 2.2× 268 1.4× 91 0.5× 316 2.0× 38 1.8k
Karl X. Knaup Germany 18 528 0.8× 123 0.4× 145 0.7× 100 0.6× 442 2.7× 29 1.1k
Susana Constantino Rosa Santos Portugal 17 664 1.0× 464 1.6× 224 1.1× 105 0.6× 250 1.6× 41 1.3k
Vera Roginskaya United States 18 682 1.0× 191 0.7× 95 0.5× 60 0.3× 137 0.9× 28 1.1k
Maria Concetta Faniello Italy 22 719 1.1× 182 0.6× 76 0.4× 194 1.1× 361 2.2× 55 1.2k
Nilamani Jena United States 9 806 1.2× 339 1.2× 138 0.7× 67 0.4× 114 0.7× 13 1.2k
Kerry Blanchard United States 11 632 1.0× 316 1.1× 79 0.4× 85 0.5× 159 1.0× 14 1.0k
Marina Cinelli Italy 16 404 0.6× 169 0.6× 167 0.9× 113 0.6× 131 0.8× 32 884

Countries citing papers authored by Scott Wise

Since Specialization
Citations

This map shows the geographic impact of Scott Wise's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott Wise with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott Wise more than expected).

Fields of papers citing papers by Scott Wise

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott Wise. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott Wise. The network helps show where Scott Wise may publish in the future.

Co-authorship network of co-authors of Scott Wise

This figure shows the co-authorship network connecting the top 25 collaborators of Scott Wise. A scholar is included among the top collaborators of Scott Wise based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott Wise. Scott Wise is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Caldwell, Timothy M., Yu Mi Ahn, Stacie L. Bulfer, et al.. (2022). Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT). Bioorganic & Medicinal Chemistry Letters. 74. 128928–128928. 19 indexed citations
3.
Smith, Bryan D., Michael D. Kaufman, Scott Wise, et al.. (2021). Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages. Molecular Cancer Therapeutics. 20(11). 2098–2109. 40 indexed citations
4.
Harney, Allison S., George S. Karagiannis, Jeanine Pignatelli, et al.. (2017). The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors. Molecular Cancer Therapeutics. 16(11). 2486–2501. 105 indexed citations
5.
Sandage, Bobby W., et al.. (2017). Abstract 2619: Combination of ECP1014 and anti-PD-L1 reduces tumor growth in the CT26 murine colon carcinoma model of a cold tumor. Cancer Research. 77(13_Supplement). 2619–2619. 3 indexed citations
6.
Draper, David E., et al.. (2016). Preclinical assessment of anti-tumor activity and immune response in syngeneic tumor models. European Journal of Cancer. 69. S97–S97. 1 indexed citations
7.
Cortes, Jörge E., Moshe Talpaz, Hedy Smith, et al.. (2016). Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. Haematologica. 102(3). 519–528. 31 indexed citations
8.
Wise, Scott, et al.. (2015). Anti-Jk3 in a Filipino man. Immunohematology. 31(3). 119–122. 2 indexed citations
9.
Bai, Yun, Geethani Bandara, Eunice C. Chan, et al.. (2012). Targeting the KIT activating switch control pocket: a novel mechanism to inhibit neoplastic mast cell proliferation and mast cell activation. Leukemia. 27(2). 278–285. 25 indexed citations
10.
Eide, Christopher A., Lauren T. Adrian, Jeffrey Tyner, et al.. (2011). The ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance Profile. Cancer Research. 71(9). 3189–3195. 77 indexed citations
11.
Ahn, Yu Mi, Michael Clare, Carol L. Ensinger, et al.. (2010). Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region. Bioorganic & Medicinal Chemistry Letters. 20(19). 5793–5798. 26 indexed citations
12.
Corson, Joseph M., Darren Flynn, Scott Wise, et al.. (2010). AXL regulates mesothelioma proliferation and invasiveness. Oncogene. 30(14). 1643–1652. 71 indexed citations
13.
Turner, Benjamin A., et al.. (2008). Examination of Edge Effects with Different Storage Conditions of Preplated Dimethyl Sulfoxide Nanospots in ChemLib 1,536- and 3,456-Well Assay-Ready Plates. Assay and Drug Development Technologies. 6(6). 811–818. 7 indexed citations
14.
O’Hare, Thomas, Christopher A. Eide, Scott Wise, et al.. (2008). Activation switch pocket inhibitors target the T315I mutant of BCR-ABL. Cancer Research. 68. 4867–4867. 1 indexed citations
15.
Wise, Scott, et al.. (2007). Simultaneous Screening of Multiple Bacterial tRNA Synthetases Using an Escherichia coli S30-Based Transcription and Translation Assay. Assay and Drug Development Technologies. 5(4). 515–522. 3 indexed citations
16.
Camp, Heidi S., et al.. (2000). Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone.. Diabetes. 49(4). 539–547. 192 indexed citations
17.
Smith, Leia M., Scott Wise, Denver T. Hendricks, et al.. (1999). cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene. 18(44). 6063–6070. 183 indexed citations
18.
Wise, Scott, et al.. (1998). Identification of domains of c-Jun mediating androgen receptor transactivation. Oncogene. 16(15). 2001–2009. 30 indexed citations
19.
Bubulya, Athanasios, et al.. (1996). c-Jun Can Mediate Androgen Receptor-induced Transactivation. Journal of Biological Chemistry. 271(40). 24583–24589. 91 indexed citations
20.
Levine, Milton Gjelhaug, et al.. (1955). Mucopolysaccharides in Tissue Cultures of Human and Mammalian Synovial Membrane.. Experimental Biology and Medicine. 89(2). 261–263. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Karoline Kollmann Breakdown of academic impact, for papers by Severa Bunda Breakdown of academic impact, for papers by Annelie Abrahamsson Breakdown of academic impact, for papers by Karl X. Knaup Breakdown of academic impact, for papers by Susana Constantino Rosa Santos Breakdown of academic impact, for papers by Vera Roginskaya Breakdown of academic impact, for papers by Maria Concetta Faniello Breakdown of academic impact, for papers by Nilamani Jena Breakdown of academic impact, for papers by Kerry Blanchard Breakdown of academic impact, for papers by Marina Cinelli
Rankless by CCL
2026